SciFi Futures
← Concepts
Biotech & Medicine

On-demand replacement organs

Any failing organ swapped for a fresh one as routine maintenance, so that bodies are repaired indefinitely from a supply that never runs short.

In shortOn-demand replacement organs, from A Gift from Earth (Larry Niven, 1968) and Ringworld (Larry Niven, 1970), is at technology readiness level 3 of 9 (experimental proof of concept) at its weakest link. Held back by Directed vascular morphogenesis. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $8.5B–33B.

On Plateau, the ruling crew's indefinite lifespans depend on organ banks stocked from executed colonists, and the supply pressure drives the whole society - the novel's premise is what happens when replacement organs come only from people.
A Gift from Earth by Larry Niven, 1968Set in 2400On track374 years left to climb 5 TRL steps (74.8 yrs/step)
Known Space medicine treats organ replacement and autodoc repair as ordinary, with organ banks and boosterspice keeping people functional for centuries.
Ringworld by Larry Niven, 1970Set in 2850On track824 years left to climb 5 TRL steps (164.8 yrs/step)

Closest todayARPA-H PRINT began funding attempts at human-sized printed kidneys, livers and hearts in January 2026 after stating that no such organ has been made; current engineered tissue is centimetre-scale.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • Capillary networks cannot be printed and must be made to self-assemble, which is the central unsolved step
    • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
    • Engineered endothelium is thrombogenic, so perfused constructs clot
    • No method guides anastomosis of a construct's vasculature to host vessels at scale
    TRL 3
  • A supply that does not depend on donors means building organs, which has never been done at human scale
    ✕4 blockers›
    • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
    • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
    • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
    • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
    TRL 4
    • Without a capillary network, tissue thicker than a few hundred microns dies
      TRL 3
    • Banked-cell organs are not patient-matched, so acceptance must be engineered
      ✕3 blockers›
      • Chronic antibody-mediated rejection proceeds even under current immunosuppression
      • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
      • No assay predicts which recipients can be safely weaned off drugs
      TRL 5
    • One organ needs 10^10-10^11 clinical-grade cells of several types
      ✕3 blockers›
      • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
      • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
      • Cost per cell at current media and reagent prices makes a printed organ unaffordable
      TRL 6
  • Each organ needs 10^10-10^11 clinical-grade cells of several types
    TRL 6
  • Banked-cell organs are not patient-matched, and lifelong immunosuppression defeats the purpose
    TRL 5
  • Routine replacement at population scale cannot be rate-limited by surgeon hours
    ✕4 blockers›
    • Demonstrations use cadaveric or marked tissue - bleeding, smoke and deforming live anatomy are untested
    • No perception system reliably identifies critical structures (duct versus artery) at the certainty surgery requires
    • Diagnosis, anesthesia and post-operative management remain outside the loop, so the system is not a self-contained doctor
    • No regulatory pathway exists for a device making irreversible intraoperative decisions
    TRL 5
    • Tissue handling, clipping and suturing demand fine force-controlled manipulation
      ✕2 blockers›
      • Robot training data at scale
      • Tactile sensing and robust hands
      TRL 5
      • Fine force control and slip detection need touch
        ✕3 blockers›
        • Elastomer skins wear out and need recalibration after thousands of contacts
        • Wiring and bandwidth for thousands of taxels across a whole hand
        • Few large tactile datasets to train manipulation policies
        TRL 5
      • Generalist perception and planning
        ✕2 blockers›
        • Reliability and calibration over long horizons
        • Continual learning after deployment
        TRL 7
        • Training and inference compute
          ✕2 blockers›
          • Grid power and interconnection queues
          • Advanced-node chip and HBM memory supply
          TRL 8
    • Safe autonomy needs to see structures beneath the exposed surface
      ✕3 blockers›
      • Optical scattering caps high-resolution imaging at a few millimetres of tissue depth
      • MRI gives depth but not video-rate cell-scale resolution, and excludes magnetic actuation hardware
      • Tracking swarms rather than single objects has no demonstrated method
      TRL 5
    • Task decomposition and language-conditioned policies are what made autonomous phases work
      TRL 7

Who could unlock it

  • Across several requirements:
  • ARPA-H PRINT 3
  • PrintBio 2
Directed vascular morphogenesisTRL 3bottleneck
  • Christopher ChenResearcher, Boston University and Wyss Institute
    Co-leads the Wyss 3D Organ Engineering Initiative and built vascular-engraftment-on-chip models of how engineered vessels connect to host tissue; elected to the National Academy of Medicine in 2025
  • Jennifer LewisResearcher, Harvard John A. Paulson School of Engineering and Applied Sciences
    Developed SWIFT and co-SWIFT sacrificial-ink printing, which write perfusable and cell-lined channels through dense cellular matrices
  • ARPA-H PRINTProgram
    Up to 176.8 million dollars over five years across five teams, with capillary-scale vasculature named as the central unmet challenge
  • Wyss Institute 3D Organ Engineering InitiativeAcademic lab
    Where the printing and the endothelial biology are combined; its ReConstruct adipose programme is the nearest clinical translation of printed vasculature
Biofabrication of vascularized human organsTRL 4
  • ARPA-H PRINTProgram
    Awarded five teams up to 176.8 million dollars over five years in January 2026 to attempt what the agency says has not been done, a human-sized functional printed organ
  • Anthony AtalaResearcher, Wake Forest Institute for Regenerative Medicine
    Principal investigator of the award of up to 24.8 million dollars announced January 2026 to produce clinical-grade vascularised renal tissue
  • Wyss InstituteAcademic lab
    PRINT awardee engineering universal clinical-scale liver tissue from adult stem cells as an implantable therapy
  • Carnegie Mellon UniversityAcademic lab
    PRINT awardee building a cost-effective immune-silent bioprinted liver for acute liver failure, targeting first-in-human within five years
Durable transplant immune toleranceTRL 5
  • Medeor TherapeuticsStartup
    Its Phase 3 MDR-101 trial left 15 of 20 HLA-matched living-donor kidney recipients functionally tolerant and off all immunosuppression two years after withdrawal, with no graft loss or GVHD (Am J Transplant, 2025)
  • Dixon KaufmanResearcher, University of Wisconsin-Madison
    First author of the MDR-101 Phase 3 report (2025), the first randomised controlled demonstration of durable drug-free tolerance in kidney transplantation
  • Megan SykesResearcher, Columbia Center for Translational Immunology
    Pioneered minimal-conditioning mixed chimerism and xenogeneic thymic transplantation for tolerance; awarded the 2025 Starzl Prize for the path to xenograft tolerance
  • Tatsuo KawaiResearcher, Legorreta Center for Clinical Transplant Tolerance, Massachusetts General Hospital
    Runs the combined kidney and bone-marrow tolerance protocols across HLA barriers and operated on the 2025 engineered-porcine-kidney recipients
Clinical-grade cell manufacturing at organ scaleTRL 6
  • ARPA-H PRINTProgram
    Program worth up to $176.8M over five years, with awards from September 2025 through 2026, that funds cell generation and large-scale cell manufacturing explicitly because current batch sizes fall short of one organ
  • CellaresStartup
    Raised a $257M Series D in January 2026 ($612M total) for automated Smart Factories; its Cell Shuttle holds FDA Advanced Manufacturing Technology designation and delivered its first GMP clinical doses in April 2026
  • LonzaCompany
    The largest contract manufacturer of cell and gene therapies, and the organisation whose unit costs and batch sizes define what clinical-grade means today
  • Vertex PharmaceuticalsCompany
    Manufactures stem-cell-derived islet cells (zimislecel) at clinical scale, the closest existing example of making a large differentiated-cell dose to pharmaceutical standard

Beyond engineering

  • Organ markets and the harvesting pressure the novel dramatizes, which real scarcity still creates
  • Reimbursement for a manufactured organ with no precedent in pricing